title: A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study.
abstract: The objective of this phase II multicenter study was to assess the efficacy and tolerance of triptorelin (a sustained-release LHRH agonist) in advanced or recurrent endometrial cancer. A total of 101 monthly intramuscular injections were administered to 24 eligible patients (median number/patient = 3; range 1-12). Mainly due to progression, only 16 patients received 3 or more injections. Among the 23 evaluable patients, 1 complete and 1 partial response (response rate of 8.7%) and 5 disease stabilizations were observed, often of long duration, but never in an irradiated area or after progestogens treatment failure. Median survival for eligible patients was 7.2 months (range: 1-36 months). Only grade 1 toxicities possibly related to the treatment were observed in 4 patients. In conclusion, triptorelin was safe, well tolerated, and easily manageable, and the very low toxicity did not impair the quality of life in these patients with a very poor prognosis. Although the response rate was disappointing, several patients showed early evidence of efficacy which may be of long duration. Response rates range between 0 and 45% in different published studies. Additional studies with stricter inclusion criteria and a larger sample size are necessary to better evaluate the role of LHRH agonists in endometrial adenocarcinomas.
authors.affiliation: Institut Gustave Roussy, Villejuif Cedex, France.
authors.forename: C
authors.initials: C
authors.lastname: Lhommé
authors.forename: P
authors.initials: P
authors.lastname: Vennin
authors.forename: N
authors.initials: N
authors.lastname: Callet
authors.forename: T
authors.initials: T
authors.lastname: Lesimple
authors.forename: J L
authors.initials: JL
authors.lastname: Achard
authors.forename: J
authors.initials: J
authors.lastname: Chauvergne
authors.forename: E
authors.initials: E
authors.lastname: Luporsi
authors.forename: P
authors.initials: P
authors.lastname: Chinet-Charrot
authors.forename: B
authors.initials: B
authors.lastname: Coudert
authors.forename: J E
authors.initials: JE
authors.lastname: Couette
authors.forename: J P
authors.initials: JP
authors.lastname: Guastalla
authors.forename: D
authors.initials: D
authors.lastname: Lebrun
authors.forename: S
authors.initials: S
authors.lastname: Ispas
authors.forename: J
authors.initials: J
authors.lastname: Blumberg
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D018450:Disease Progression; D016889:Endometrial Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005602:France; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000188:drug therapy*; D017329:Triptorelin Pamoate / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017329:Triptorelin Pamoate; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone